Brigid Bio is a biotech spin-out from the University of Aberdeen, developing first in class antibody-based drugs as safer and efficacious treatment solutions for high-risk and drug resistant fungal infections.
We have developed a unique and proprietary drug discovery platform and identified key cell wall markers as novel drug targets which are fungal pathogen specific and critical for infection and resistance. Our lead human monoclonal antibodies to these targets have proven efficacy in a ‘clinically predictive’ in vivo infection model.
Brigid Bio is supported by the Scottish Enterprise High Growth Spinout Programme and led by a team of globally recognized scientific expertise and commercial experience.
Company Details
- Employees
- 2
- Address
- Foresterhill Road, Liberty Building,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.brigidbio.com
- Keywords
- Monoclonal antibodies, invasive fungal infections, AMR, antimicrobial resistance, anti-infectives, Biologics therapies, drug resistant fungi, infections in immunocompromised patients.
- HQ
- Aberdeen, Outside the US or Canada
Brigid Bio Questions
Brigid Bio's website is http://www.brigidbio.com
Brigid Bio's LinkedIn profile is https://uk.linkedin.com/company/brigid-bio
Brigid Bio has
2 employees.
View email and phone details for 2
employees at Brigid Bio.
Brigid Bio's industry is
Biotechnology Research
Brigid Bio's top competitors are
Epitogenx,
Myomaker Bio,
M2i2,
Microplate Dx Limited,
Incate,
Paralos Bioscience,
Glykogen Limited,
Avenue Biosciences,
Omnicin Therapeutics,
Theralia Ab.
Brigid Bio's categories are Biotechnology Research
